AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

The pharmaceutical giant expects overall sales and core earnings per share to rise by a high-teens percentage at constant ...

This was accelerated by demand for its cancer blockbuster drugs Imfinzi, Tagrisso and Calquence. Analysts had expected core earnings per share at $2.04 on sales of $13.1 billion, according to a ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.